Dr. Bora Lim, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 78
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license Q1852 (first issued 2014; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 78
- Services billed
- 158
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 66 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Houston, TX | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 10 payments worth $14,998 in total to this clinician.
| Gilead Sciences, Inc. | $13,435 |
|---|---|
| Daiichi Sankyo Inc. | $1,417 |
| Immunitybio, Inc. | $83.48 |
| Stemline Therapeutics Inc. | $61.33 |
| Consulting Fee | $14,407 |
|---|---|
| Food and Beverage | $375 |
| Travel and Lodging | $216 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Jul 2, 2025 | Consulting FeeCompany’s description;4200492;GTF;10814925 | $9,985 |
| Gilead Sciences, Inc. May 21, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4148040;VEM US;10814925 | $3,050 |
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee | $1,372 |
| Gilead Sciences, Inc. May 16, 2025 | Travel and Lodging Trodelvy · ONC · travel to Houston, TX · in-kind Company’s description;4147957;VEM US;10814925 | $180 |
| Gilead Sciences, Inc. May 28, 2025 | Travel and Lodging Trodelvy · ONC · travel to Houston, TX Company’s description;4147041;VEM US;10814925 | $35.35 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $638,502 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast …
Merck Sharp & Dohme LLC - BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Beone Medicines Ltd. · Recruiting · NCT06756932 - A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.